152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma. (December 2022)

Record Type:: Journal Article
Title:: 152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma. (December 2022)
Main Title:: 152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma
Authors:: Bixia, T.
Chi, Z.
Chen, Y.
Jiang, Y.
Fang, M.
Gao, Q.
Huang, G.
Ren, X.
Yao, Y.
Chen, J.
Zhang, X.
Li, R.
Humphrey, G.
Ding, L.
Geng, Y.
Zhao, S.
Yang, Y.
Lu, Z.
Ye, D.
Guo, J.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100264 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24685.xml